By far the most common question I get from those who have received one of the COVID-19 vaccines is, “How do you get it out of your body. The mRNA and adenoviral DNA products are presented without any idea of how or when the body will ever break down the genetic code. Synthetic mRNA carried by lipid nanoparticles appears to be resistant to degradation by human ribonucleases by design, so that the product would be long-lived and produce the protein product of interest for a significant period of time.
This would be an advantage for a normal human protein that is replaced in a rare condition of genetic deficiency (eg alpha galactosidase in Fabry disease). However, it is a big problem when the protein is the pathogenic spike of SARS-CoV-2. Adenoviral DNA (Janssen) is supposed to be cleaved by deoxyribonuclease, however, this has not been extensively studied.
This leaves spike protein dissolution as a therapeutic target for vaccine injury. In respiratory infection, the spike is processed and activated by cellular proteases including transmembrane serine protein 2, cathepsin, and furin. By vaccination, these systems can be bypassed by systematic application and production of spiked proteins inside the cells. As a result, the pathogenesis of vaccine injury syndrome is believed to be driven by the accumulation of spike proteins in cells, tissues, and organs.
Nattokinase is an enzyme produced by fermentation of soybeans with the bacterium Bacillus subtilis var. natto and was available as an oral supplement. It breaks down fibrinogen, factor VII, cytokines and factor VIII, and has been studied for its cardiovascular benefits. Of all the available therapies that I have used in my practice and of all the suggested detoxification agents, I believe nattokinase and related peptides hold the most promise for patients at this time.
Tanikava et al. investigated the effect of nattokinase on the SARS-CoV-2 spike protein. In the first experiment, they showed that the spike was degraded in a time- and dose-dependent manner in a cell lysate preparation that could be analogous to the vaccine recipient. Another experiment showed that nattokinase degrades the spike protein in cells infected with SARS-CoV-2. This was repeated in a similar study by Ob and his colleagues in 2021.
Nattokinase is dosed in fibrinolytic units (FU) per gram and may vary depending on purity. Kurosawa et al showed in humans that after a single oral dose of 2000 FU, D-dimer concentrations at six and eight hours, respectively, as well as fibrin/fibrinogen breakdown products in the blood increased significantly (p < 0.05, respectively) four hours after administration. . ).
Therefore, the empirical starting dose may be 2000 FU twice daily. Full pharmacokinetic and pharmacodynamic studies have not been completed, but several years of marketed use as an over-the-counter supplement suggest that nattokinase is safe with the major caveats of excessive bleeding and caution with concomitant antiplatelet and anticoagulant medications.
Based on these findings, nattokinase and similar products such as serrapeptase should undergo well-funded, accelerated preclinical and clinical development programs. The problem is the urgency of time, similar to SARS-CoV-2 infection and empiric early therapy. It will take up to 20 years to obtain a fully developed pharmaceutical profile to characterize the safety and efficacy of nattokinase in the treatment of vaccination injury and post-COVID syndrome.
A large number of people are now ill, and many believe that empirical treatment is justified given the sufficiently low risk of side effects and the potentially high reward. My recommendation is to discuss this with your doctor or seek out a holistic or naturopathic medical professional who has experience with the safety profile of nattokinase in a variety of applications.